QIAGEN (QGEN) Insider Plans to Sell 25,000 Shares Valued at $1.22M

Rhea-AI Filing Summary

Form 144 filed for QGEN reports a proposed sale of 25,000 common shares on the New York Stock Exchange with an aggregate market value of $1,220,000 and approximately 216,834,000 shares outstanding. The securities to be sold were acquired as restricted stock unit (RSU) awards on multiple dates in 2021 and 2022, with individual lots of 5,918; 5,247; 5,089; 4,253; and 4,493 shares. The filer states no securities were sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer. The planned transaction is scheduled for approximately 08/15/2025.

Positive

• Proposed sale is limited in size: 25,000 shares represent a very small percentage of the 216,834,000 outstanding shares
• Securities originate from RSU awards, showing the lots were issued as compensation rather than acquired in opportunistic transactions
• No sales in the past three months reported by the filer

Negative

• None.

Insights

Financial Analyst

TL;DR: A small, planned insider sale from RSU awards totaling 25,000 shares valued at $1.22M; no recent sales reported.

The filing documents a proposed sale of 25,000 common shares representing roughly 0.0115% of the 216.834M outstanding shares, indicating this is a modest insider liquidity event rather than a large disposition. The lots originated from RSU awards vested on 02/15/2021, 02/28/2022 and 03/31/2022, which supports that the shares are routine compensatory issuances rather than open-market purchases. The filer reports no sales in the prior three months and certifies no undisclosed material adverse information.

Corporate Governance Expert

TL;DR: Transaction appears procedural and compliant with Rule 144 disclosures; filer gives the standard attestation.

The notice provides required Rule 144 details: class, broker, number of shares, aggregate value, acquisition dates and nature (RSU awards), and an approximate sale date. The inclusion of the filer attestation about lack of undisclosed material information and the absence of recent sales align with standard compliance expectations. No governance red flags or extraordinary departures from disclosure norms are evident in the provided data.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Moors & Cabot, Inc. One Federal Street, 19th Floor Boston MA 02110	25000	1220000	216834000	08/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/15/2021	RSU Award	Issuer			5918	02/15/2021	Not Applicable
Common	02/28/2022	RSU Award	Issuer			5247	02/28/2022	Not Applicable
Common	02/28/2022	RSU Award	Issuer			5089	02/28/2022	Not Applicable
Common	02/28/2022	RSU Award	Issuer			4253	02/28/2022	Not Applicable
Common	03/31/2022	RSU Award	Issuer			4493	03/31/2022	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is the size and value of the proposed QGEN sale reported on the Form 144?

The filer proposes to sell 25,000 common shares with an aggregate market value of $1,220,000.

When is the approximate sale date listed on the QGEN Form 144?

The approximate date of sale is listed as 08/15/2025.

How many QIAGEN shares are outstanding according to this filing?

The filing reports 216,834,000 shares outstanding.

What is the origin of the shares being sold in the Form 144?

All reported lots were acquired as RSU awards on dates in 2021 and 2022 (02/15/2021, 02/28/2022, 03/31/2022).

Were any shares sold by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.